Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Pautler Cohen Findlay and Eichenbaum MDS PA

Neither a doctor nor a teaching hospital

Research payments

$5,738,311

1,687 payments

Through program year 2025, Pautler Cohen Findlay and Eichenbaum MDS PA is reported as receiving $5,738,311 in research payments, across 1,687 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $2,554,882 1,334
2024 Research $814,378 211
2023 Research $863,046 64
2022 Research $668,044 28
2021 Research $661,315 47
2020 Research $176,646 3

Breakdown

Who paid Research payments · program years 2020–2025
  1. Regeneron Pharmaceuticals, Inc. $2,593,514 1,223 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $1,469,310 232 payments
  3. Kyowa Kirin, Inc. $798,149 186 payments
  4. Novartis Pharmaceuticals Corporation $497,040 3 payments
  5. EyePoint Pharmaceuticals US, Inc. $218,265 2 payments
  6. Mylan Technologies Inc. $63,037 29 payments
  7. Sanofi US Services Inc. $58,658 4 payments
  8. Genentech, Inc. $33,171 7 payments
  9. Mylan Inc. $7,167 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) $1,631,673 760 payments
  2. A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $861,252 297 payments
  3. BAY865321, HD 8mg, AMD - Ph 3 $807,766 53 payments
  4. A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration $422,617 99 payments
  5. A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema $375,532 87 payments
  6. BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration $303,683 67 payments
  7. BAY 865321, Aflibercept 8mg in RVO $252,931 82 payments
  8. An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to MacUlar Edema Secondary to Branch Retinal Vein Occlusion (Raptor) $240,378 1 payment
  9. A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD $218,265 2 payments
  10. An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to MacUlar Edema Secondary to Branch Retinal Vein Occlusi $153,536 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record